276872-89-0

Basic information

• Product Name: N-BOC-3-METHYLENE-PIPERIDINE
• Synonyms: 3-Methylene-1-piperidinecarboxylic acid tert-butyl ester;1-Boc-3-Methylenepiperidi...;tert-butyl 3-Methylidenepiperidine-1-carboxylate;tert-butyl 3-methylenepiperidine-1-carboxylate (N-BOC-3-methylene piperidine);N-BOC-3-METHYLENE-PIPERIDINE;1-Boc-3-methylenepiperidine;3-Methylenepiperidine-1-carboxylic acid tert-butyl ester;1-Piperidinecarboxylic acid, 3-methylene-, 1,1-dimethylethyl ester
• CAS NO: 276872-89-0
• Molecular Formula: C₁₁H₁₉NO₂
• Molecular Weight: 197.27406
• Mol File: 276872-89-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 257.6°C at 760 mmHg
• Flash Point: 109.6°C
• Appearance: /
• Density: 1g/cm³
• Vapor Pressure: 0.0144mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.46±0.20(Predicted)
• CAS DataBase Reference: N-BOC-3-METHYLENE-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-3-METHYLENE-PIPERIDINE(276872-89-0)
• EPA Substance Registry System: N-BOC-3-METHYLENE-PIPERIDINE(276872-89-0)

Safety Data

• Hazardous Substances Data: 276872-89-0(Hazardous Substances Data)

Usage

Description

N-BOC-3-METHYLENE-PIPERIDINE, also known as 1-Boc-3-methylenepiperidine, is an organic compound that serves as a crucial reagent in the synthesis of various pharmaceutical compounds. It is characterized by its unique molecular structure, which includes a piperidine ring with a methylene group at the 3-position and a tert-butoxycarbonyl (BOC) protecting group at the nitrogen atom. This structure makes it a versatile building block in the development of novel drugs and bioactive molecules.

Uses

Used in Pharmaceutical Industry:
N-BOC-3-METHYLENE-PIPERIDINE is used as a reagent for the preparation of analogs of spirocyclic quinuclidinyl-Δ2-isoxazolines. These analogs are potent and selective α7 nicotinic agonists, which have potential applications in the treatment of various neurological and cognitive disorders, such as Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). The compound's unique structure allows for the development of new drugs with improved efficacy, safety, and selectivity.

InChI:InChI=1/C11H19NO2/c1-9-6-5-7-12(8-9)10(13)14-11(2,3)4/h1,5-8H2,2-4H3

Upstream product

• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 2065-66-9 methyl-triphenylphosphonium iodide 
• 357289-93-1 (2-bromo-2-propenyl)-(3-phenylselenopropyl)amine 
• 357289-94-2 N-(3-phenylselenopropyl)-2-methyleneaziridine 
• 357289-92-0 3-[N-(2-bromo-2-propenyl)amino]propan-1-ol 
• 15031-81-9 3-methylenepiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1174718-00-3 4-(1-Boc-3-piperidinemethyl)-2-(4-chlorophenyl)-thieno[2,3-d]pyridazine-7-carboxylic acid ethyl ester 
• 1258322-85-8 tert-butyl 3-phenyl-1-oxa-2,7-diazaspiro[4.5]dec-2-ene-7-carboxylate 
• 1258322-86-9 3-phenyl-1-oxa-2,7-diazaspiro[4.5]dec-2-ene 
• 1350474-77-9 3-phenyl-7-methyl-1-oxa-2,7-diazaspiro[4.5]dec-2-ene 
• 1350474-91-7 C₁₅H₂₁N₂O⁽¹⁺⁾*I^(1-) 
• 1383688-30-9 1-(3-benzyl-5,6-dihydropyridin-1(2H)-yl)-2,2-dimethylpropan-1-one 
• 1170044-32-2 3-(benzo[d][1,3]dioxol-5-ylmethyl)piperidine hydrochloride 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 
• 1419101-54-4 tert-butyl 2-hydroxy-6-azaspiro[3.5]nonane-6-carboxylate 
• 1359704-84-9 tert-butyl 2-oxo-6-azaspiro[3.5]nonane-6-carboxylate 

Relevant articles and documents

Intramolecular radical rearrangement reactions of 2-methyleneaziridines: Application to the synthesis of substituted piperidines, decahydroquinolines, and octahydroindolizines

(matrix presented) Intramolecular 5-exo cyclization of 3-(2-methyleneaziridin-1-yl)propyl radicals leads to the generation of a highly strained, bicyclic aziridinylcarbinyl radical that undergoes C-N bond fission to the ring-expanded aminyl radical. This

Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders

Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.

SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS

The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl) ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers